David M. Morens

David M. Morens

Auto-generated profile, based on publicly available information

David M. Morens

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell
Verified
Journal Article
Closed access
DMDavid M. Morens
David M. Morens
AFAnthony S. Fauci
Anthony S. Fauci

4 July 2013 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DMDavid M. Morens
David M. Morens
AFAnthony S. Fauci
Anthony S. Fauci

1 April 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
DMDavid M. Morens
David M. Morens
AFAnthony S. Fauci
Anthony S. Fauci
The 1918–1919 H1N1 influenza pandemic was among the most deadly events in recorded human history, killing an estimated 50–100 million persons. Becaus

24 January 2017 in Annual Review of Pathology: Mechanisms of Disease
Verified
Journal Article
Closed access
LBLaura Baseler
Laura Baseler
DCDaniel S. Chertow
Daniel S. Chertow
KJKarl M. Johnson
Karl M. Johnson
HFHeinz Feldmann
Heinz Feldmann
DMDavid M. Morens
David M. Morens
For almost 50 years, ebolaviruses and related filoviruses have been repeatedly reemerging across the vast equatorial belt of the African continent to cause epidemics of highly fatal hemorrhagic fever. The 2013-2015 West African epidemic, by far the most geographically extensive, most fatal, and longest lasting epidemic in Ebola's history, presented an enormous international public health challenge, but it also provided insights into Ebola's pathogenesis and natural history, clinical expression, treatment, prevention, and control. Growing understanding of ebolavirus pathogenetic mechanisms and important new clinical observations of the disease course provide fresh clues about prevention and treatment approaches. Although viral cytopathology and immune-mediated cell damage in ebolavirus disease often result in severe compromise of multiple organs, tissue repair and organ function recovery can be expected if patients receive supportive care with fluids and electrolytes; maintenance of oxygenation and tissue perfusion; and respiratory, renal, and cardiovascular support. Major challenges for managing future Ebola epidemics include establishment of early and aggressive epidemic control and earlier and better patient care and treatment in remote, resource-poor areas where Ebola typically reemerges. In addition, it will be important to further develop Ebola vaccines and to adopt policies for their use in epidemic and pre-epidemic situations.

1 November 2008 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DMDavid M Morens
David M Morens
GFGregory K Folkers
Gregory K Folkers
AFAnthony S Fauci
Anthony S Fauci

2 September 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
DMDavid M. Morens
David M. Morens
JBJoel G. Breman
Joel G. Breman
Charles H. CalisherCharles H. Calisher
Charles H. Calisher
PDPeter C. Doherty
Peter C. Doherty
BHBeatrice Hahn
Beatrice Hahn
JTJeffery K Taubenberger
Jeffery K Taubenberger
The COVID-19 pandemic is among the deadliest infectious diseases to have emerged in recent history. As with all past pandemics, the specific mechanism of its emergence in humans remains unknown. Nevertheless, a large body of virologic, epidemiologic, veterinary, and ecologic data establishes that the new virus, SARS-CoV-2, evolved directly or indirectly from a β-coronavirus in the sarbecovirus (SARS-like virus) group that naturally infect bats and pangolins in Asia and Southeast Asia. Scientists have warned for decades that such sarbecoviruses are poised to emerge again and again, identified risk factors, and argued for enhanced pandemic prevention and control efforts. Unfortunately, few such preventive actions were taken resulting in the latest coronavirus emergence detected in late 2019 which quickly spread pandemically. The risk of similar coronavirus outbreaks in the future remains high. In addition to controlling the COVID-19 pandemic, we must undertake vigorous scientific, public health, and societal actions, including significantly increased funding for basic and applied research addressing disease emergence, to prevent this tragic history from repeating itself.